Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)

Caroline E. Grant, Mian Gao, Marianne K. DeGorter, Susan P. C. Cole and Roger G. Deeley
Drug Metabolism and Disposition December 2008, 36 (12) 2571-2581; DOI: https://doi.org/10.1124/dmd.108.022491
Caroline E. Grant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mian Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne K. DeGorter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan P. C. Cole
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger G. Deeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Multidrug resistance proteins (MRPs) are members of the “C” branch of the ATP-binding cassette transporter superfamily. Human MRP1 transports a wide range of natural product drugs and structurally diverse conjugated and unconjugated organic anions. Its closest relative is MRP3. Despite their structural similarity, the homologs differ substantially in their substrate specificity. It is noteworthy that MRP1 transports glutathione (GSH) and GSH conjugates and displays GSH-stimulated transport of a number of unconjugated and conjugated compounds. In contrast, MRP3 does not transport GSH and is a poor transporter of GSH conjugates. However, both proteins transport glucuronide conjugates, such as 17β-estradiol 17-(β-d-glucuronide). We have constructed a series of MRP1/MRP3 hybrids and used them to identify a region of MRP1 that is critical for binding and transport of GSH conjugates such as leukotriene C4 (LTC4). Substitution of this region encompassing transmembrane helices 8 and 9 and portions of cytoplasmic loops 4 and 5 of MRP1 with the equivalent region of MRP3 eliminated LTC4 transport. Transport of other substrates was either unaffected or enhanced. We identified three residues in this region: Tyr440, Ile441, and Met443, mutation of which differentially affected transport. It is noteworthy that substitution of Tyr440 with Phe, as found in MRP3, reduced LTC4 and GSH-stimulated estrone-3-sulfate transport without affecting transport of other substrates tested. The mutation increased the Km for LTC4 5-fold and substantially reduced photolabeling of MRP1 by both [3H]LTC4 and the GSH derivative, azidophenacyl-[35S]GSH. These results suggest that Tyr440 makes a major contribution to recognition of GSH and the GSH moiety of conjugates such as LTC4.

Footnotes

  • This work was supported by a grant from the Canadian Institutes of Health Research (MOP-62824).

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.108.022491.

  • ABBREVIATIONS: ABC, ATP-binding cassette; MRP, multidrug resistance protein; GSH, glutathione; LTC4, cysteinyl leukotriene C4; E217βG, estradiol-17β-d-glucuronide; E13SO4, estrone 3-sulfate; MTX, methotrexate; VP-16, etoposide; MSD, membrane-spanning domain; TM, transmembrane; NBD, nucleotide-binding domain; SUR, sulfonylurea receptor; HEK, human embryonic kidney; β-gus, β-glucuronidase; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; mAb, monoclonal antibody.

  • ↵ Embedded Image The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

  • ↵1 Current affiliation: Gene Expression and Protein Biochemistry, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey.

  • ↵2 Current affiliation: University of Western Ontario, London, Ontario, Canada.

    • Received May 31, 2008.
    • Accepted September 4, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 36 (12)
Drug Metabolism and Disposition
Vol. 36, Issue 12
1 Dec 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)

Caroline E. Grant, Mian Gao, Marianne K. DeGorter, Susan P. C. Cole and Roger G. Deeley
Drug Metabolism and Disposition December 1, 2008, 36 (12) 2571-2581; DOI: https://doi.org/10.1124/dmd.108.022491

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)

Caroline E. Grant, Mian Gao, Marianne K. DeGorter, Susan P. C. Cole and Roger G. Deeley
Drug Metabolism and Disposition December 1, 2008, 36 (12) 2571-2581; DOI: https://doi.org/10.1124/dmd.108.022491
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics